Author: admin

Shares of Edge Therapeutics Inc. plummeted 87% in active premarket trade toward a record low Wednesday, after an independent data monitoring committee recommended a phase 3 study of its treatment in adults with aneurysmal subarachnoid hemorrhage be stopped because data showing the trial had a “low probability” of meeting its primary endpoint. The stock was the most active ahead of the open with 2.1 million shares traded. Based on the committee’s recommendation, Edge said it has decided to discontinue the NEWTON 2 study. The company will analyst the data from the study to better understand the outcome. “We are very disappointed that the NEWTON 2 study did not demonstrate evidence of improved outcomes with EG-1962, given the positive findings demonstrated on this measure in our randomized, open-label Phase 1/2 NEWTON study of EG-1962 in a similar patient population,” said Chief Executive Brian Leuthner. The stock, which went public Oct. 1, 2015 at an initial public offering price of $11, had soared 94% over the past 12 months through Tuesday, while the iShares Nasdaq Biotechnology ETF had climbed 8.0% and the S&P 500 had gained 11%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of Edge Therapeutics Inc. plummeted 87% in active premarket trade toward a record low Wednesday, after an independent data monitoring committee recommended a phase 3 study of its treatment in adults with aneurysmal subarachnoid hemorrhage be stopped because data showing the trial had a “low probability” of meeting its primary endpoint. The stock was the most active ahead of the open with 2.1 million shares traded. Based on the committee’s recommendation, Edge said it has decided to discontinue the NEWTON 2 study. The company will analyst the data from the study to better understand the outcome. “We are very disappointed that the NEWTON 2 study did not demonstrate evidence of improved outcomes with EG-1962, given the positive findings demonstrated on this measure in our randomized, open-label Phase 1/2 NEWTON study of EG-1962 in a similar patient population,” said Chief Executive Brian Leuthner. The stock, which went public Oct. 1, 2015 at an initial public offering price of $11, had soared 94% over the past 12 months through Tuesday, while the iShares Nasdaq Biotechnology ETF had climbed 8.0% and the S&P 500 had gained 11%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement, the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations: Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area. ], the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations — Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement, the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations: Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area. ], the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations — Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement The Federal Bureau of Investigation said it has arrested a Seattle man in connection with a series of suspicious packages that were sent to U.S. military sites in the Washington, D.C. area on Monday. In a press statement, the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations: Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area. ], the FBI said 43-year old Thanh Cong Phan, was taken into custody on Monday, and that the packages found contained “potential destructive devices.” Multiple packages were sent to the following locations — Joint Base Anacostia-Bolling and Lesley J. McNair, both in D.C. and the Naval Surface Warfare Center, the Central Intelligence Agency and Fort Belvoir, all in Virginia. The FBI said it’s continuing a joint investigation with the U.S. Postal Inspection Service and cautioned that further packages could have been mailed to mail processing facilities in the D.C. metro area.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News